Featured Research

from universities, journals, and other organizations

Novel nanoparticle delivers powerful RNA interference drugs

Date:
July 9, 2013
Source:
Sanford-Burnham Medical Research Institute
Summary:
Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference.

Silencing genes that have malfunctioned is an important approach for treating diseases such as cancer and heart disease. One effective approach is to deliver drugs made from small molecules of ribonucleic acid, or RNA, which are used to inhibit gene expression. The drugs, in essence, mimic a natural process called RNA interference.

In a new paper appearing today online in the journal, ACS Medicinal Chemistry Letters, researchers at Sanford-Burnham Medical Research Institute have developed nanoparticles that appear to solve a big challenge in delivering the RNA molecules, called small interfering RNA, or siRNA, to the cells where they are needed. By synthesizing a nanoparticle that releases its siRNA cargo only after it enters targeted cells, Dr. Tariq M. Rana and colleagues showed in mice that they could deliver drugs that silenced the genes they wanted.

"Our study describes a strategy to reduce toxic effects of nanoparticles, and deliver a cargo to its target," said Dr. Rana, whose paper, "In Vivo Delivery of RNAi by Reducible Interfering Nanoparticles (iNOPs)," also included contributions from researchers at the University of Massachusetts Medical School and the University of California at San Diego. "We've found a way to release the siRNA compounds, so it can be more effective where it's needed," Dr. Rana said.

In their experiment, the team synthesized what they call interfering nanoparticles, or iNOPs, made from repetitively branched molecules of a small natural polymer called poly-L-lysine. The iNOPs were specially designed with positively charged residues connected by disulfide bonds and these iNOPS assemble into a complex with negatively charged siRNA molecules. It's the bonds that ensure that the siRNA molecules remain with the nanoparticle, named iNOP-7DS. However, once inside targeted cells, a naturally occurring and abundant antioxidant called glutathione breaks the bond, releasing the siRNA molecules. In their experiment, Dr. Rana and colleagues showed in the lab that iNOP-7DS is reducible -- that is, the disulfide bonds holding the siRNA molecules can be broken.

They next showed that iNOP-7DS can be delivered effectively inside cultured murine liver cells, where the siRNA molecules silenced a gene called ApoB. This gene has been notoriously difficult to regulate in liver cells with small molecule drugs; high levels of the protein that ApoB encodes can lead to plaques that cause vascular disease.

Dr. Rana's lab further showed in tests that their nanoparticle remained stable in serum, suggesting that it is not degraded in the bloodstream. Finally, the researchers showed in tests with mice that their nanoparticle iNOP-7DS can be delivered effectively to the liver, spleen, and lung; and it suppressed the level of messenger RNA involved in the expression of the ApoB gene. In their in vivo experiment, they found that extremely small doses of siRNA were effective.

The next step, Dr. Rana said, is to increase the efficacy of iNOP-7DS in other in vivo experiments. "We would like to target not only ApoB, but cancer causing genes as well and in other tissues. That is the next goal." By marshaling the naturally occurring phenomenon of RNA interference, scientists are developing new ways to silence errant gene expression involved in illnesses. The nanoparticles developed by Dr. Rana and colleagues offer a potential new strategy for delivering this powerful therapeutic approach.


Story Source:

The above story is based on materials provided by Sanford-Burnham Medical Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Huricha Baigude, Jie Su, Joshua McCarroll, Tariq M. Rana. In Vivo Delivery of RNAi by Reducible Interfering Nanoparticles (iNOPs). ACS Medicinal Chemistry Letters, 2013; 130708140502006 DOI: 10.1021/ml4001003

Cite This Page:

Sanford-Burnham Medical Research Institute. "Novel nanoparticle delivers powerful RNA interference drugs." ScienceDaily. ScienceDaily, 9 July 2013. <www.sciencedaily.com/releases/2013/07/130709115855.htm>.
Sanford-Burnham Medical Research Institute. (2013, July 9). Novel nanoparticle delivers powerful RNA interference drugs. ScienceDaily. Retrieved April 17, 2014 from www.sciencedaily.com/releases/2013/07/130709115855.htm
Sanford-Burnham Medical Research Institute. "Novel nanoparticle delivers powerful RNA interference drugs." ScienceDaily. www.sciencedaily.com/releases/2013/07/130709115855.htm (accessed April 17, 2014).

Share This



More Matter & Energy News

Thursday, April 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

German Researchers Crack Samsung's Fingerprint Scanner

German Researchers Crack Samsung's Fingerprint Scanner

Newsy (Apr. 16, 2014) German researchers have used a fake fingerprint made from glue to bypass the fingerprint security system on Samsung's new Galaxy S5 smartphone. Video provided by Newsy
Powered by NewsLook.com
Porsche CEO Says Supercar Is Not Dead: Cue the Spyder 918

Porsche CEO Says Supercar Is Not Dead: Cue the Spyder 918

TheStreet (Apr. 16, 2014) The Porsche Spyder 918 proves that, in an automotive world obsessed with fuel efficiency, the supercar is not dead. Porsche North America CEO Detlev von Platen attributes the brand's consistent sales growth -- 21% in 2013 -- with an investment in new technology and expanded performance dynamics. The hybrid Spyder 918 has 887 horsepower and 944 lb-ft of torque, but it can run 18 miles on just an electric charge. The $845,000 vehicle is not a consumer-targeted vehicle but a brand statement. Video provided by TheStreet
Powered by NewsLook.com
Industry's Optimism Shines At New York Auto Show

Industry's Optimism Shines At New York Auto Show

Newsy (Apr. 16, 2014) After seeing auto sales grow last month, there's plenty for the industry to celebrate as it rolls out its newest designs. Video provided by Newsy
Powered by NewsLook.com
Ford Mustang Fetes Its 50th Atop Empire State Building

Ford Mustang Fetes Its 50th Atop Empire State Building

AFP (Apr. 16, 2014) Ford celebrated the 50th birthday of its beloved Mustang by displaying a new model of the convertible on top of the Empire State Building in New York. Duration: 00:28 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins